Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

被引:141
作者
Bajaj, M. [1 ]
Suraamornkul, S. [1 ]
Hardies, L. J. [1 ]
Glass, L. [1 ]
Musi, N. [1 ]
DeFronzo, R. A. [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, Diabet Div, San Antonio, TX USA
关键词
adiponectin; insulin sensitivity; PPAR-alpha; PPAR-gamma; type; 2; diabetes;
D O I
10.1007/s00125-007-0698-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis The aim of the study was to examine the effects of pioglitazone (PTO), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, and fenofibrate (FENO), a PPAR-alpha agonist, as monotherapy and in combination on glucose and lipid metabolism. Subjects and methods Fifteen type 2 diabetic patients received FENO (n = 8) or PTO (n = 7) for 3 months, followed by the addition of the other agent for 3 months in an open-label study. Subjects received a 4 h hyperinsulinaemic-euglycaemic clamp and a hepatic fat content measurement at 0, 3 and 6 months. Results Following PTO, fasting plasma glucose (FPG) (p<0.05) and HbA(1c) (p<0.01) decreased, while plasma adiponectin (AD) (5.5 +/- 0.9 to 13.8 +/- 3.5 mu g/ml [SEM], p<0.03) and the rate of insulin-stimulated total-body glucose disposal (Rd) (23.8 +/- 3.8 to 40.5 +/- 4.4 mu mol kg(-1) min(-1), p<0.005) increased. After FENO, FPG, HbA(1c), AD and Rd did not change. PTO reduced fasting NEFA (784 +/- 53 to 546 +/- 43 mu mol/l, p<0.05), triacylglycerol (2.12 +/- 0.28 to 1.61 +/- 0.22 mmol/l, p<0.05) and hepatic fat content (20.4 +/- 4.8 to 10.2 +/- 2.5%, p<0.02). Following FENO, fasting NEFA and hepatic fat content did not change, while triacylglycerol decreased (2.20 +/- 0.14 to 1.59 +/- 0.13 mmol/l, p<0.01). Addition of FENO to PTO had no effect on Rd, FPG, HbA(1c), NEFA, hepatic fat content or AD, but triacylglycerol decreased (1.61 +/- 0.22 to 1.00 +/- 0.15 mmol/l, p<0.05). Addition of PTO to FENO increased Rd (24.9 +/- 4.4 to 36.1 +/- 2.2 mu mol kg(-1) min(-1) p<0.005) and AD (4.1 +/- 0.8 to 13.1 +/- 2.5 mu g/ml, p<0.005) and reduced FPG (p<0.05), MAI, (p<0.05), NEFA (p<0.01), hepatic fat content (18.3 +/- 3.1 to 13.5 +/- 2.1%, p<0.03) and triacylglycerol (1.59 0.13 to 0.96 +/- 0.9 mmol/l, p<0.01). Muscle adenosine 5'-monophospbate-activated protein kinase (AMPK) activity did not change following FENO; following the addition of PTO, muscle AMPK activity increased significantly (phosphorylated AMPK:total AMPK ratio 1.2 +/- 0.2 to 2.2 +/- 0.3,p<0.01). Conclusions/interpretation We conclude that PPAR-alpha therapy has no effect on NEFA or glucose metabolism and that addition of a PPAR-alpha agonist to a PPAR-alpha agent causes a further decrease in plasma triacylglycerol, but has no effect on NEFA or glucose metabolism.
引用
收藏
页码:1723 / 1731
页数:9
相关论文
共 53 条
[1]   Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - No alteration in adipose tissue of obese and NIDDM patients [J].
Auboeuf, D ;
Rieusset, J ;
Fajas, L ;
Vallier, P ;
Frering, V ;
Riou, JP ;
Staels, P ;
Auwerx, J ;
Laville, M ;
Vidal, H .
DIABETES, 1997, 46 (08) :1319-1327
[2]  
Auwerx J, 1996, J Atheroscler Thromb, V3, P81
[3]   INSULIN ACTION AND GLUCOSE-METABOLISM ARE IMPROVED BY GEMFIBROZIL TREATMENT IN HYPERTRIGLYCERIDEMIC PATIENTS [J].
AVOGARO, A ;
BELTRAMELLO, P ;
BONANOME, A ;
BIFFANTI, S ;
MARIN, R ;
ZAMBON, S ;
CONFORTIN, L ;
MANZATO, E ;
CREPALDI, G ;
TIENGO, A .
ATHEROSCLEROSIS, 1995, 113 (01) :117-124
[4]   Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients [J].
Bajaj, M ;
Suraamornkul, S ;
Piper, P ;
Hardies, LJ ;
Glass, L ;
Cersosimo, E ;
Pratipanawatr, T ;
Miyazaki, Y ;
Defronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :200-206
[5]   Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes [J].
Bajaj, M ;
Suraamornkul, S ;
Pratipanawatr, T ;
Hardies, LJ ;
Pratipanawatr, W ;
Glass, L ;
Cersosimo, E ;
Miyazaki, Y ;
DeFronzo, RA .
DIABETES, 2003, 52 (06) :1364-1370
[6]   Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach [J].
Bays, H ;
Mandarino, L ;
DeFronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :463-478
[7]   Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes [J].
Buse, JB ;
Rubin, CJ ;
Frederich, R ;
Viraswami-Appanna, K ;
Lin, KC ;
Montoro, R ;
Shockey, G ;
Davidson, JA .
CLINICAL THERAPEUTICS, 2005, 27 (08) :1181-1195
[8]   Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats [J].
Choi, KC ;
Ryu, OH ;
Lee, KW ;
Kim, HY ;
Seo, JA ;
Kim, SG ;
Kim, NH ;
Choi, DS ;
Baik, SH ;
Choi, KM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 336 (03) :747-753
[9]   WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice [J].
Chou, CJ ;
Haluzik, M ;
Gregory, C ;
Dietz, KR ;
Vinson, C ;
Gavrilova, O ;
Reitman, ML .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :24484-24489
[10]   Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes [J].
Civitarese, AE ;
Jenkinson, CP ;
Richardson, D ;
Bajaj, M ;
Cusi, K ;
Kashyap, S ;
Berria, R ;
Belfort, R ;
DeFronzo, RA ;
Mandarino, LJ ;
Ravussin, E .
DIABETOLOGIA, 2004, 47 (05) :816-820